Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HPV Vaccine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : University Medical Centre Ljubljana
Deal Size : Inapplicable
Deal Type : Inapplicable
HPV Infections and Vaccine Attitudes In Slovenian Women Post Vaccination
Details : HPV Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : HPV Vaccine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : University Medical Centre Ljubljana
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Rabin Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Keytruda
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Rabin Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nonavalent Hpv Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nonavalent Hpv Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Nonavalent Hpv Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NOUS-209,MVA-209-FSP,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Nouscom AG
Deal Size : Undisclosed
Deal Type : Collaboration
Details : NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : NOUS-209,MVA-209-FSP,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Nouscom AG
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ATG-037,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Antengene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemoth...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 26, 2022
Lead Product(s) : ATG-037,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Antengene
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is i...
Product Name : Lynparza
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR30303,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Zhejiang Doer Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : DR30303,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Zhejiang Doer Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
Product Name : Lynparza
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PMC-309,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : PharmAbcine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : PMC-309,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : PharmAbcine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Nykode Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Nykode Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration